Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology Free

Abstract

Urokinase-type plasminogen activator/severe combined immunodeficiency (uPA/SCID) mice transplanted with human hepatocytes are permissive for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, one of the problems affecting uPA transgenic mice is the expansion of mouse hepatocyte colonies due to homologous recombination of the uPA gene. In this study, we attempted to infect HBV and HCV in humanized cDNA-uPA/SCID mice, a novel uPA transgenic mouse model designed to overcome this disadvantage. Three hundred and eighty-six uPA/SCID and 493 cDNA-uPA/SCID mice were transplanted with human hepatocytes and then injected with either HBV- or HCV-positive human serum samples or HBV-transfected cell culture medium. Twelve weeks after human hepatocyte transplantation, the mouse serum concentration of human albumin, which is correlated with the degree of repopulation by human hepatocytes, was significantly higher in cDNA-uPA/SCID mice compared with uPA/SCID mice. HBV-infected cDNA-uPA/SCID mice showed significantly greater and more persistent viraemia, and similar virological effects by entecavir treatment were achieved in both systems. HCV-infected cDNA-uPA/SCID mice developed more frequent and significantly higher viraemia compared with uPA/SCID mice. The present study using a large number of mice showed that cDNA-uPA/SCID mice transplanted with human hepatocytes developed high and long-term persistent viraemia following HBV and HCV infection, and a higher survival rate was observed in cDNA-uPA/SCID compared with uPA/SCID mice. These mice may be a useful animal model for the study of HBV and HCV virology and the analysis of the effect of antiviral drugs.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000726
2017-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/5/1040.html?itemId=/content/journal/jgv/10.1099/jgv.0.000726&mimeType=html&fmt=ahah

References

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212–2219 [View Article][PubMed]
    [Google Scholar]
  2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333–1342 [View Article][PubMed]
    [Google Scholar]
  3. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32:1106–1110 [View Article][PubMed]
    [Google Scholar]
  4. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132–2137 [View Article][PubMed]
    [Google Scholar]
  5. Dandri M, Lütgehetmann M, Petersen J. Experimental models and therapeutic approaches for HBV. Semin Immunopathol 2013; 35:7–21 [View Article][PubMed]
    [Google Scholar]
  6. Vercauteren K, de Jong YP, Meuleman P. HCV animal models and liver disease. J Hepatol 2014; 61:S26–S33 [View Article][PubMed]
    [Google Scholar]
  7. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7:927–933 [View Article][PubMed]
    [Google Scholar]
  8. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165:901–912 [View Article][PubMed]
    [Google Scholar]
  9. Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M et al. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 2011; 405:405–410 [View Article][PubMed]
    [Google Scholar]
  10. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M et al. Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice. Nat Biotechnol 2007; 25:903–910 [View Article][PubMed]
    [Google Scholar]
  11. Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007; 104:20507–20511 [View Article][PubMed]
    [Google Scholar]
  12. Vercauteren K, de Jong YP, Meuleman P. Animal models for the study of HCV. Curr Opin Virol 2015; 13:67–74 [View Article][PubMed]
    [Google Scholar]
  13. Allweiss L, Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol 2016; 64:S17–S31 [View Article][PubMed]
    [Google Scholar]
  14. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL et al. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991; 66:245–256 [View Article][PubMed]
    [Google Scholar]
  15. Strom SC, Davila J, Grompe M. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 2010; 640:491–509 [View Article][PubMed]
    [Google Scholar]
  16. Tateno C, Kawase Y, Tobita Y, Hamamura S, Ohshita H et al. Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice. PLoS One 2015; 10:e0142145 [View Article][PubMed]
    [Google Scholar]
  17. Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S et al. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 2011; 54:764–771 [View Article][PubMed]
    [Google Scholar]
  18. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99:15669–15674 [View Article][PubMed]
    [Google Scholar]
  19. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139:499–509 [View Article][PubMed]
    [Google Scholar]
  20. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101:6669–6674 [View Article][PubMed]
    [Google Scholar]
  21. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005; 42:1046–1054 [View Article][PubMed]
    [Google Scholar]
  22. Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E et al. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. Biochem Biophys Res Commun 2013; 441:230–235 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000726
Loading
/content/journal/jgv/10.1099/jgv.0.000726
Loading

Data & Media loading...

Most cited Most Cited RSS feed